Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.

Vormoor, Britta; Schlosser, Yvonne T; Blair, Helen; Sharma, Abhishek; Wilkinson, Sarah; Newell, David R; Curtin, Nicola

Vormoor, Britta; Schlosser, Yvonne T; Blair, Helen; Sharma, Abhishek; Wilkinson, Sarah; Newell, David R; Curtin, Nicola.

Afiliação

Vormoor B; Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
Schlosser YT; Department of Paediatric and Adolescent Haematology and Oncology, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Blair H; German Cancer Research Center, DKFZ, Cell Cycle Control and Carcinogenesis, Heidelberg, Germany.
Sharma A; Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
Wilkinson S; NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Newell DR; Northumbria University, Department of Health and Life Sciences, Newcastle upon Tyne, UK.
Curtin N; Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Newcastle upon Tyne, UK.

Oncotarget ; 8(69): 113418-113430, 2017 Dec 26.

Article em En | MEDLINE | ID: mdl-29371919

Palavras-chave

DNA-PK inhibitor; NU7441; PARP-inhibitor; ewing sarcoma; rucaparib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google